📣 VC round data is live. Check it out!
- Public Comps
- Immuneering
Immuneering Valuation Multiples
Discover revenue and EBITDA valuation multiples for Immuneering and similar public comparables like Oryzon Genomics, Panacea Biotec, Prelude Therapeutics, IMBiologics and more.
Immuneering Overview
About Immuneering
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
Founded
2008
HQ

Employees
66
Website
Financials (LTM)
EV
$124M
Valuation Multiples
Start free trialImmuneering Financials
Immuneering reported last 12-month revenue of -.
In the same LTM period, Immuneering generated - in gross profit and had net loss of ($65M).
Revenue (LTM)
Immuneering P&L
In the most recent fiscal year, Immuneering reported revenue of - and EBITDA of ($59M).
Immuneering is unprofitable as of last fiscal year, with EBITDA margin of - and net margin of -.
Financial data powered by Morningstar, Inc.
Immuneering Stock Performance
Immuneering has current market cap of $277M, and enterprise value of $124M.
Market Cap Evolution
Immuneering's stock price is $4.28.
Immuneering share price decreased by 26.0% in the last 30 days, and increased by 27.0% in the last year.
Immuneering has an EPS (earnings per share) of $-0.87.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $124M | $277M | -4.8% | -26.0% | -18.8% | 27.0% | $-0.87 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialImmuneering Valuation Multiples
Immuneering trades at (2.1x) EV/EBITDA.
EV / Revenue (LTM)
Immuneering Financial Valuation Multiples
As of June 3, 2026, Immuneering has market cap of $277M and EV of $124M.
Immuneering has a P/E ratio of (4.3x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Immuneering Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Immuneering Margins & Growth Rates
Immuneering grew net profit by 38% in the last fiscal year.
Immuneering Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Immuneering Operational KPIs
Immuneering's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.9M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Immuneering Competitors
Immuneering competitors include Oryzon Genomics, Panacea Biotec, Prelude Therapeutics, IMBiologics, Santhera Pharma, Zentalis Pharma, Eledon Pharmaceuticals, Surrozen, SAB Bio and Organogenesis.
Most Immuneering public comparables operate across Biopharmaceuticals, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| - | 78.6x | (44.4x) | (25.5x) | |||
| 3.9x | - | 79.5x | - | |||
| 17.8x | 11.3x | (2.1x) | (2.0x) | |||
| - | 27.6x | - | - | |||
| 3.2x | 2.9x | (7.8x) | (11.9x) | |||
| - | - | (0.7x) | (0.7x) | |||
| - | - | (2.0x) | - | |||
| 48.5x | 35.8x | (4.1x) | - | |||
This data is available for Pro users. Sign up to see all Immuneering competitors and their valuation data. Start Free Trial | ||||||
Immuneering VC Funding History
Before going public, Immuneering raised $82M in total equity funding, across 2 rounds.
Immuneering Funding Rounds
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Immuneering
| When was Immuneering founded? | Immuneering was founded in 2008. |
| Where is Immuneering headquartered? | Immuneering is headquartered in United States. |
| How many employees does Immuneering have? | As of today, Immuneering has over 66 employees. |
| Who is the CEO of Immuneering? | Immuneering's CEO is Benjamin J. Zeskind. |
| Is Immuneering publicly listed? | Yes, Immuneering is a public company listed on Nasdaq. |
| What is the stock symbol of Immuneering? | Immuneering trades under IMRX ticker. |
| When did Immuneering go public? | Immuneering went public in 2021. |
| Who are competitors of Immuneering? | Immuneering main competitors include Oryzon Genomics, Panacea Biotec, Prelude Therapeutics, IMBiologics, Santhera Pharma, Zentalis Pharma, Eledon Pharmaceuticals, Surrozen, SAB Bio, Organogenesis. |
| What is the current market cap of Immuneering? | Immuneering's current market cap is $277M. |
| Is Immuneering profitable? | No, Immuneering is not profitable. |
| What is the current net income of Immuneering? | Immuneering's last 12 months net income is ($65M). |
| How many companies Immuneering has acquired to date? | Immuneering hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Immuneering has invested to date? | Immuneering hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Immuneering
Lists including Immuneering
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.